Skip to content
ApprovedFDA approvedStrong evidence

Memantine

Prescription Alzheimer's medicine that eases glutamate overload of nerve cells and modestly slows decline.

NootropicNeuroprotectionNeuroprotectionMemoryGlutamateNMDADopamine
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassNeuroprotection · Memory
Primary targetNMDA receptor uncompetitive low-affinity antagonism
Targets4 receptor targets
Half-life~60-100 hours
OnsetGradual; steady state is reached over days to weeks with titration
EvidenceStrong evidence
Affected systemsGlutamateNMDADopamine

Contents

DETAILED OVERVIEW

What is Memantine?

Memantine is a prescription medicine approved for moderate-to-severe Alzheimer's disease: by the US FDA in 2003, and by the European Medicines Agency (EMA) as well. Brand names include Namenda, Ebixa and Axura. It is not a controlled narcotic and is not on the anti-doping list.

Long-lasting, low-level overstimulation by glutamate, one of the brain's main excitatory messengers, can damage nerve cells. Memantine dampens this while letting through the strong, short signals needed for learning. In trials it modestly slowed the decline in thinking and daily functioning, but it does not reverse the disease; it is often given together with another Alzheimer's medicine such as donepezil. It is generally well tolerated, but may cause dizziness, headache or confusion. Caution is needed in severe kidney failure because the drug can build up, and its safety in pregnancy and breastfeeding is not established.

Mechanism

NMDA antagonist (uncompetitive, low-affinity)

Half-life

~60-100 hours

Legal status

Prescription drug (FDA/EMA approved)

Receptor profile

  • NMDA receptorsStrong
  • Excess glutamate / excitotoxic calcium influxStrong
  • 5-HT3 and α7 nicotinic acetylcholine receptorsWeak
  • Dopamine (indirect)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Dizziness
  • Headache
  • Confusion or cognitive slowing, especially at higher doses
  • Constipation
  • Somnolence, less often restlessness or agitation
  • Occasional rise in blood pressure

Contraindications · 4

  • Severe renal impairment: dose reduction required, risk of accumulation
  • Pregnancy and breastfeeding: safety not established, use only if clearly needed
  • History of seizures: use with caution
  • Known hypersensitivity to memantine

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Memantine is a prescription drug approved for moderate-to-severe Alzheimer's disease. It calms down excessive activity of a brain chemical (glutamate) that can overstimulate and damage nerve cells, and this can modestly slow the decline in thinking and daily functioning. It's generally well tolerated and is often combined with other Alzheimer's medications like donepezil.

Telegram

Have a question about Memantine?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC12H21N
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.